January 12, 2026

OWP Pharmaceuticals Announces Commercial Product Availability of SUBVENITE® (lamotrigine) Oral Suspension in U.S. Market

Share this press release:

Document loads below this notification. If you are not able to see the document below, please reload page.

Additional Press Releases

September 18, 2025 / Press Release

OWP Pharmaceuticals Announces FDA Approval of SUBVENITE® (lamotrigine) Oral Suspension

May 20, 2024 / Press Release

OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension

August 1, 2023 / Press Release

OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD